Stents as a platform for drug delivery
暂无分享,去创建一个
Lei Lei | Fei Lu | Lei Lei | Sheng-Rong Guo | Wei-Luan Chen | Hao-Jun Rong | Fei Lu | Shengjie Guo | Wei-luan Chen | Haojun Rong
[1] U. Siebert,et al. Randomized comparison of dexamethasone-eluting stents with bare metal stent implantation in patients with acute coronary syndrome: serial angiographic and sonographic analysis. , 2007, American heart journal.
[2] Shengrong Guo,et al. 5-Fluorouracil-loaded multilayered films for drug controlled releasing stent application: Drug release, microstructure, and ex vivo permeation behaviors. , 2010, Journal of controlled release : official journal of the Controlled Release Society.
[3] P. Serruys,et al. Drug-Eluting Stent Update 2007: Part I: A Survey of Current and Future Generation Drug-Eluting Stents: Meaningful Advances or More of the Same? , 2007, Circulation.
[4] A. Baumbach,et al. Stent‐based antirestenotic coatings (sirolimus/paclitaxel) , 2002, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.
[5] L. Buellesfeld,et al. ABT-578-Eluting Stents , 2004, Herz.
[6] Rossella Fattori,et al. Drug-eluting stents in vascular intervention , 2003, The Lancet.
[7] N. Krott,et al. Long-term assessment of a novel biodegradable paclitaxel-eluting coronary polylactide stent. , 2004, European heart journal.
[8] Liping Tang,et al. Review: Bioresorbable polymeric stents: current status and future promise , 2003, Journal of biomaterials science. Polymer edition.
[9] Actinomycin-eluting stent for coronary revascularization: a randomized feasibility and safety study: the ACTION trial. , 2004, Journal of the American College of Cardiology.
[10] R. Erbel,et al. Synergistic effects of a novel nanoporous stent coating and tacrolimus on intima proliferation in rabbits , 2003, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.
[11] R. Waksman. Current state of the absorbable metallic (magnesium) stent. , 2009, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.
[12] Patrick W Serruys,et al. Coronary stents: looking forward. , 2010, Journal of the American College of Cardiology.
[13] John A Ormiston,et al. First‐in‐human implantation of a fully bioabsorbable drug‐eluting stent: The BVS poly‐L‐lactic acid everolimus‐eluting coronary stent , 2007, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.
[14] S. Çalış,et al. Development of biodegradable drug releasing polymeric cardiovascular stents and in vitro evaluation , 2009, Journal of microencapsulation.
[15] O. Bayrak,et al. A new application for urethral strictures: tacrolimus-eluting stent. , 2010, Journal of endourology.
[16] P. Serruys,et al. Biodegradable-polymer-based, paclitaxel-eluting Infinnium stent: 9-Month clinical and angiographic follow-up results from the SIMPLE II prospective multi-centre registry study. , 2006, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.
[17] F. Boey,et al. In vitro and in vivo performance of a dual drug-eluting stent (DDES). , 2010, Biomaterials.
[18] L. Machan. Clinical experience and applications of drug-eluting stents in the noncoronary vasculature, bile duct and esophagus. , 2006, Advanced drug delivery reviews.
[19] Y. Yoon,et al. Local Gene Transfer of phVEGF-2 Plasmid by Gene-Eluting Stents: An Alternative Strategy for Inhibition of Restenosis , 2004, Circulation.
[20] A. Abizaid,et al. New Drug-Eluting Stents: An Overview on Biodegradable and Polymer-Free Next-Generation Stent Systems , 2010, Circulation. Cardiovascular interventions.
[21] G. Dangas,et al. Real world safety and efficacy of the Janus tacrolimus‐eluting stent: Long‐term clinical outcome and angiographic findings from the tacrolimus‐eluting stent (TEST) registry , 2009, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.
[22] A. Kastrati,et al. A polymer-free dual drug-eluting stent in patients with coronary artery disease: a randomized trial vs. polymer-based drug-eluting stents. , 2008, European heart journal.
[23] P. Mather,et al. Tailored drug release from biodegradable stent coatings based on hybrid polyurethanes. , 2009, Journal of controlled release : official journal of the Controlled Release Society.
[24] P. Serruys,et al. Advances in stent drug delivery: the future is in bioabsorbable stents. , 2009, Expert Opinion on Drug Delivery.
[25] R. Schwartz,et al. OrbusNeich fully absorbable coronary stent platform incorporating dual partitioned coatings. , 2009, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.
[26] Franz Schwarz,et al. Comparison of a polymer‐free rapamycin‐eluting stent (YUKON) with a polymer‐based paclitaxel‐eluting stent (TAXUS) in real‐world coronary artery lesions , 2008, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.
[27] T. Kurata,et al. Effectiveness of statin-eluting stent on early inflammatory response and neointimal thickness in a porcine coronary model. , 2008, Circulation journal : official journal of the Japanese Circulation Society.
[28] G. Reid,et al. In-vitro activity of triclosan-eluting ureteral stents against common bacterial uropathogens. , 2006, Journal of endourology.
[29] P. Hwang,et al. Controlled Steroid Delivery via Bioabsorbable Stent: Safety and Performance in a Rabbit Model , 2009, American journal of rhinology & allergy.
[30] Sang Joon Park,et al. Efficacy of a Dexamethasone-Eluting Nitinol Stent on the Inhibition of Pseudointimal Hyperplasia in a Transjugular Intrahepatic Portosystemic Shunt: An Experimental Study in a Swine Model , 2005, Korean journal of radiology.
[31] Robert C. Eberhart,et al. Bioresorbable Microporous Stents Deliver Recombinant Adenovirus Gene Transfer Vectors to the Arterial Wall , 1998, Annals of Biomedical Engineering.
[32] M. Böhm,et al. Atorvastatin stent coating does not reduce neointimal proliferation after coronary stenting , 2003, Zeitschrift für Kardiologie.
[33] J. E. Sousa,et al. Preliminary results of the hydroxyapatite nonpolymer-based sirolimus-eluting stent for the treatment of single de novo coronary lesions a first-in-human analysis of a third-generation drug-eluting stent system. , 2008, JACC. Cardiovascular interventions.
[34] S. Jain,et al. Biodegradable-polymer-based, sirolimus-eluting Supralimus stent: 6-month angiographic and 30-month clinical follow-up results from the series I prospective study. , 2008, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.
[35] M. Beijk,et al. XIENCE V everolimus-eluting coronary stent system: a novel second generation drug-eluting stent , 2007, Expert review of medical devices.
[36] W. Kao,et al. Drug release kinetics and transport mechanisms of non-degradable and degradable polymeric delivery systems , 2010, Expert opinion on drug delivery.
[37] D. Holmes. Interventional cardiology: A new drug-eluting stent that does not live up to its promise , 2009, Nature Reviews Cardiology.
[38] J. Gunn,et al. Stent coatings and local drug delivery; state of the art. , 1999, European heart journal.
[39] Subbu Venkatraman,et al. Collapse pressures of biodegradable stents. , 2003, Biomaterials.
[40] Shengrong Guo,et al. In vitro and in vivo evaluation of praziquantel loaded implants based on PEG/PCL blends. , 2010, International journal of pharmaceutics.
[41] M. Hong,et al. First human experience with angiopeptin‐eluting stent: A quantitative coronary angiography and three‐dimensional intravascular ultrasound study , 2005, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.
[42] P. Serruys,et al. Abstract 5998: Final Results of the HEALING 2B Trial to Evaluate a Bioengineered CD34 Antibody Coated Stent (GenousTMStent) Designed to Promote Vascular Healing by Capture of Circulating Endothelial Progenitor Cells in CAD Patients , 2008 .
[43] C. Fiori,et al. Heparin coating on ureteral Double J stents prevents encrustations: an in vivo case study. , 2008, Journal of endourology.
[44] Shengrong Guo,et al. A type of esophageal stent coating composed of one 5-fluorouracil-containing EVA layer and one drug-free protective layer: in vitro release, permeation and mechanical properties. , 2007, Journal of controlled release : official journal of the Controlled Release Society.
[45] A. Connolly,et al. Introducing the first polymer-free leflunomide eluting stent. , 2008, Atherosclerosis.
[46] R. Kuntz,et al. Zotarolimus (ABT-578) eluting stents. , 2006, Advanced drug delivery reviews.
[47] M. Feldman,et al. Delivery of paclitaxel from cobalt-chromium alloy surfaces without polymeric carriers. , 2010, Biomaterials.
[48] Y. Byun,et al. The short-term effects on restenosis and thrombosis of echinomycin-eluting stents topcoated with a hydrophobic heparin-containing polymer. , 2007, Biomaterials.
[49] L. P. Tan,et al. Controlled release of sirolimus from a multilayered PLGA stent matrix. , 2006, Biomaterials.
[50] N. Kipshidze,et al. Estrogen‐eluting, phosphorylcholine‐coated stent implantation is associated with reduced neointimal formation but no delay in vascular repair in a porcine coronary model , 2002, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.
[51] S. Milz,et al. Inhibition of Neointima Formation by a Novel Drug-Eluting Stent System That Allows for Dose-Adjustable, Multiple, and On-Site Stent Coating , 2005, Arteriosclerosis, thrombosis, and vascular biology.
[52] G. Gerken,et al. Impact of a self-expanding, plastic esophageal stent on various esophageal stenoses, fistulas, and leakages: a single-center experience in 39 patients. , 2005, Gastrointestinal endoscopy.
[53] P. Fitzgerald,et al. 7-Hexanoyltaxol–Eluting Stent for Prevention of Neointimal Growth: An Intravascular Ultrasound Analysis From the Study to COmpare REstenosis rate between QueST and QuaDS-QP2 (SCORE) , 2002, Circulation.
[54] M Kellomäki,et al. Drug-eluting bioabsorbable stents - an in vitro study. , 2009, Acta biomaterialia.
[55] A randomised comparison of novolimus-eluting and zotarolimus-eluting coronary stents: 9-month follow-up results of the EXCELLA II study. , 2010, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.
[56] R. Virmani,et al. The significance of preclinical evaluation of sirolimus-, paclitaxel-, and zotarolimus-eluting stents. , 2007, The American journal of cardiology.
[57] T. Tammela,et al. Biocompatibility, encrustation and biodegradation of ofloxacine and silver nitrate coated poly-L-lactic acid stents in rabbit urethra , 2002, Urological Research.
[58] P. Serruys,et al. Final results of the HEALING IIB trial to evaluate a bio-engineered CD34 antibody coated stent (Genous™Stent) designed to promote vascular healing by capture of circulating endothelial progenitor cells in CAD patients. , 2011, Atherosclerosis.
[59] A. Seth. Moving Towards Biomimicry - The Development of the Novel BioMime™ Sirolimus-eluting Coronary Stent System Interventional Cardiology , 2010 .
[60] K. Schmitz,et al. In vitro study of drug-eluting stent coatings based on poly(l-lactide) incorporating cyclosporine A – drug release, polymer degradation and mechanical integrity , 2007, Journal of materials science. Materials in medicine.
[61] G. Stone,et al. Non–Polymer-Based Paclitaxel-Coated Coronary Stents for the Treatment of Patients With De Novo Coronary Lesions: Angiographic Follow-Up of the DELIVER Clinical Trial , 2004, Circulation.
[62] L. Buellesfeld,et al. BioMatrix® Biolimus A9®-eluting coronary stent: a next-generation drug-eluting stent for coronary artery disease , 2006, Expert review of medical devices.
[63] Changning Guo,et al. Propagation of uncertainty in nasal spray in vitro performance models using Monte Carlo simulation: Part II. Error propagation during product performance modeling. , 2010, Journal of pharmaceutical sciences.
[64] J. S. Lee,et al. Fixation of a Modified Covered Esophageal Stent: Its Clinical Usefulness for Preventing Stent Migration , 2001, Endoscopy.
[65] E. Verbeken,et al. Methotrexate loaded SAE coated coronary stents reduce neointimal hyperplasia in a porcine coronary model , 2004, Heart.
[66] A. Abizaid,et al. Novolimus™-eluting coronary stent system , 2010 .
[67] Wonkeun Song,et al. CTX-M-14 and CTX-M-15 enzymes are the dominant type of extended-spectrum β-lactamase in clinical isolates of Escherichia coli from Korea , 2009, Journal of medical microbiology.
[68] I. Menown,et al. Drug-eluting stents: the next generation , 2010 .
[69] Saibal Kar,et al. Polymer-Free Biolimus A9–Coated Stent Demonstrates More Sustained Intimal Inhibition, Improved Healing, and Reduced Inflammation Compared With a Polymer-Coated Sirolimus-Eluting Cypher Stent in a Porcine Model , 2010, Circulation. Cardiovascular interventions.
[70] F. Boey,et al. In vitro study of release mechanisms of paclitaxel and rapamycin from drug-incorporated biodegradable stent matrices. , 2004, Journal of controlled release : official journal of the Controlled Release Society.
[71] Jong Chun Park,et al. Anti-inflammatory Effect of Abciximab-Coated Stent in a Porcine Coronary Restenosis Model , 2007, Journal of Korean medical science.
[72] Pierfrancesco Agostoni,et al. The GENESIS (Randomized, Multicenter Study of the Pimecrolimus-Eluting and Pimecrolimus/Paclitaxel-Eluting Coronary Stent System in Patients with De Novo Lesions of the Native Coronary Arteries) trial. , 2009, JACC. Cardiovascular interventions.
[73] J. Wilcox,et al. The next generation Endeavor Resolute Stent: role of the BioLinx Polymer System. , 2007, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.
[74] Georg Nickenig,et al. A novel paclitaxel-eluting stent with an ultrathin abluminal biodegradable polymer 9-month outcomes with the JACTAX HD stent. , 2010, JACC. Cardiovascular interventions.
[75] John D Denstedt,et al. New developments in ureteral stent design, materials and coatings , 2006, Expert review of medical devices.
[76] S. Venkatraman,et al. Adjustable paclitaxel release kinetics and its efficacy to inhibit smooth muscle cells proliferation. , 2008, Journal of controlled release : official journal of the Controlled Release Society.
[77] S. Venkatraman,et al. Paclitaxel release from single and double-layered poly(DL-lactide-co-glycolide)/poly(L-lactide) film for biodegradable coronary stent application. , 2008, Journal of biomedical materials research. Part A.
[78] Frank Litvack,et al. Local Drug Delivery via a Coronary Stent With Programmable Release Pharmacokinetics , 2003, Circulation.
[79] Kinam Park,et al. Mechanisms of controlled drug release from drug-eluting stents. , 2006, Advanced drug delivery reviews.
[80] W. Wijns,et al. Differential effects of drug-eluting stents on local endothelium-dependent coronary vasomotion. , 2008, Journal of the American College of Cardiology.
[81] Outcomes of the tacrolimus drug-eluting Janus stent: a prospective two-centre registry in high-risk patients , 2008, Journal of cardiovascular medicine.
[82] Fuan Wang,et al. Layer-by-layer assembly of biologically inert inorganic ions/DNA multilayer films for tunable DNA release by chelation. , 2008, Journal of controlled release : official journal of the Controlled Release Society.
[83] Na Zhang,et al. Cationic polymer optimization for efficient gene delivery. , 2010, Mini reviews in medicinal chemistry.
[84] M. Zilberman,et al. Drug-eluting bioresorbable stents for various applications. , 2006, Annual review of biomedical engineering.
[85] Daniel W. Pack,et al. Design and development of polymers for gene delivery , 2005, Nature Reviews Drug Discovery.
[86] T. Cheng. Origin of the word 'stent'. , 1999, Hospital medicine.
[87] J. Barry,et al. The Taxus drug-eluting stent: a new paradigm in controlled drug delivery. , 2006, Advanced drug delivery reviews.
[88] R. A. Abd El-Baky,et al. Effect of ciprofloxacin and N-acetylcysteine on bacterial adherence and biofilm formation on ureteral stent surfaces. , 2009, Polish journal of microbiology.
[89] Dong Ki Lee,et al. The effect on porcine bile duct of a metallic stent covered with a paclitaxel-incorporated membrane. , 2005, Gastrointestinal endoscopy.
[90] David P. Martin,et al. Absorbable polymer stent technologies for vascular regeneration , 2009 .
[91] W. Roorda,et al. XIENCE V™ Stent Design and Rationale , 2009 .
[92] R. Levy,et al. Gene delivery from a DNA controlled-release stent in porcine coronary arteries , 2000, Nature Biotechnology.
[93] Ho-Young Song,et al. Influence of a dexamethasone-eluting covered stent on tissue reaction: an experimental study in a canine bronchial model , 2005, European Radiology.
[94] T. Tammela,et al. Urethral in situ biocompatibility of new drug‐eluting biodegradable stents: an experimental study in the rabbit , 2009, BJU international.
[95] Zhongmin Wang,et al. In vivo evaluation of 5-fluorouracil-containing self-expandable nitinol stent in rabbits: Efficiency in long-term local drug delivery. , 2010, Journal of pharmaceutical sciences.
[96] H Shimokawa,et al. Intramural delivery of a specific tyrosine kinase inhibitor with biodegradable stent suppresses the restenotic changes of the coronary artery in pigs in vivo. , 1998, Journal of the American College of Cardiology.
[97] Katrin Sternberg,et al. A Biodegradable Slotted Tube Stent Based on Poly(l-lactide) and Poly(4-hydroxybutyrate) for Rapid Balloon-Expansion , 2007, Annals of Biomedical Engineering.